Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly

Pasireotide long-acting release is effective in achieving biochemical control and reducing tumour volume in patients with acromegaly inadequately controlled by first-line therapy. As part of a long-term, real-world study at our centre, 20 of 50 patients receiving pasireotide benefited from a reducti...

Descripción completa

Detalles Bibliográficos
Autores principales: Marques, Nelma Veronica, Wildemberg, Luiz Eduardo Armondi, Gadelha, Monica R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503228/
https://www.ncbi.nlm.nih.gov/pubmed/37530039
http://dx.doi.org/10.1530/EC-23-0155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503228/
https://www.ncbi.nlm.nih.gov/pubmed/37530039
http://dx.doi.org/10.1530/EC-23-0155

Ejemplares similares